非小细胞肺癌靶向治疗耐药及对策的研究进展

Progress in research of drug resistance of non-small cell lung cancer to targeted therapy and the countermeasures

非小细胞肺癌是肺癌的主要类型,严重威胁人类健康。现靶向治疗广泛应用于其临床治疗,疗效显著。然而,研究表明初始靶向治疗有效的非小细胞肺癌患者可在一段时间内出现耐药,如何解决耐药问题成为研究的热点。本文综述非小细胞肺癌患者靶向治疗耐药及对策的研究进展。

Non-small cell lung cancer（ NSCLC） is the main type of lung cancer,which has threatened people＇s health seriously. Targeted therapy is widely and efficiently used in NSCLC treatment. However,recent researches have indicated that the initially efficient targeted therapy for NSCLC patients can be resistant in a period of time. How to solve the problem of drug resistance has become a hot spot for the research. In this article,we reviewed the progress in the research of the drug resistance of NSCLC and its countermeasures.